Alnylam Pharmaceuticals (ALNY) : Opus Point Partners Management scooped up 27,371 additional shares in Alnylam Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 77,593 shares of Alnylam Pharmaceuticals which is valued at $5,748,089.Alnylam Pharmaceuticals makes up approximately 4.80% of Opus Point Partners Management’s portfolio.
Other Hedge Funds, Including , Voya Investment Management boosted its stake in ALNY in the latest quarter, The investment management firm added 1,043 additional shares and now holds a total of 31,416 shares of Alnylam Pharmaceuticals which is valued at $2,327,297. Alnylam Pharmaceuticals makes up approx 0.01% of Voya Investment Management’s portfolio.Renaissance Technologies reduced its stake in ALNY by selling 195,327 shares or 91.27% in the most recent quarter. The Hedge Fund company now holds 18,673 shares of ALNY which is valued at $1,383,296.Diam Ltd. boosted its stake in ALNY in the latest quarter, The investment management firm added 38,103 additional shares and now holds a total of 44,878 shares of Alnylam Pharmaceuticals which is valued at $3,202,494. Alnylam Pharmaceuticals makes up approx 0.05% of Diam Ltd.’s portfolio. Tarbox Group sold out all of its stake in ALNY during the most recent quarter. The investment firm sold 10 shares of ALNY which is valued $681.
Alnylam Pharmaceuticals closed down -0.83 points or -1.19% at $69.02 with 3,59,276 shares getting traded on Thursday. Post opening the session at $69.8, the shares hit an intraday low of $67.81 and an intraday high of $70.6999 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Alnylam Pharmaceuticals reported $-1.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.22 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.27. The company had revenue of $8.70 million for the quarter, compared to analysts expectations of $7.98 million. The company’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.85 EPS.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Alnylam Pharmaceuticals was Initiated by Morgan Stanley to “Overweight” on Aug 2, 2016. Company shares were Reiterated by Chardan Capital Markets on May 26, 2016 to “Buy”, Firm has raised the Price Target to $ 115 from a previous price target of $93 .
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.